Cargando…
Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden?
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171449/ https://www.ncbi.nlm.nih.gov/pubmed/30278807 http://dx.doi.org/10.1080/0886022X.2018.1497518 |
| _version_ | 1783360793833635840 |
|---|---|
| author | Georgiadis, George S. Argyriou, Christos Kantartzi, Konstantia Georgakarakos, Efstratios I. |
| author_facet | Georgiadis, George S. Argyriou, Christos Kantartzi, Konstantia Georgakarakos, Efstratios I. |
| author_sort | Georgiadis, George S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6171449 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-61714492018-10-05 Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? Georgiadis, George S. Argyriou, Christos Kantartzi, Konstantia Georgakarakos, Efstratios I. Ren Fail Letter to the Editor Taylor & Francis 2018-10-03 /pmc/articles/PMC6171449/ /pubmed/30278807 http://dx.doi.org/10.1080/0886022X.2018.1497518 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Georgiadis, George S. Argyriou, Christos Kantartzi, Konstantia Georgakarakos, Efstratios I. Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| title | Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| title_full | Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| title_fullStr | Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| title_full_unstemmed | Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| title_short | Which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| title_sort | which is the most powerful adverse factor for autogenous access patency between diabetes and high arterial calcification burden? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171449/ https://www.ncbi.nlm.nih.gov/pubmed/30278807 http://dx.doi.org/10.1080/0886022X.2018.1497518 |
| work_keys_str_mv | AT georgiadisgeorges whichisthemostpowerfuladversefactorforautogenousaccesspatencybetweendiabetesandhigharterialcalcificationburden AT argyriouchristos whichisthemostpowerfuladversefactorforautogenousaccesspatencybetweendiabetesandhigharterialcalcificationburden AT kantartzikonstantia whichisthemostpowerfuladversefactorforautogenousaccesspatencybetweendiabetesandhigharterialcalcificationburden AT georgakarakosefstratiosi whichisthemostpowerfuladversefactorforautogenousaccesspatencybetweendiabetesandhigharterialcalcificationburden |